We are live on ! Find out more
NBIX icon

Neurocrine Biosciences
NBIX

218 hedge funds and large institutions have $4.7B invested in Neurocrine Biosciences in 2015 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 92 increasing their positions, 72 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

52% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 23

43% more capital invested

Capital invested by funds: $3.29B → $4.7B (+$1.41B)

29% more call options, than puts

Call options by funds: $36.2M | Put options by funds: $28.1M

28% more repeat investments, than reductions

Existing positions increased: 92 | Existing positions reduced: 72

5% more funds holding

Funds holding: 207 → 218 (+11)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

Holders
218
Holders Change
+11
Holders Change %
+5.31%
% of All Funds
5.72%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
35
Increased
92
Reduced
72
Closed
23
Calls
$36.2M
Puts
$28.1M
Net Calls
+$8.07M
Net Calls Change
-$28.1M

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$43.9M
2
Citadel Advisors
Citadel Advisors
Florida
+$33.4M
3
SAM
Sectoral Asset Management
Quebec, Canada
+$21.2M
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$20.2M
5
JHIU
Janus Henderson Investors US
Colorado
+$19.9M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$66.1M
2
PA
Perceptive Advisors
New York
-$22.7M
3
Jennison Associates
Jennison Associates
New York
-$19.2M
4
TCP
Tourbillon Capital Partners
New York
-$18M
5
Millennium Management
Millennium Management
New York
-$13.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
MOACM
101
Mutual of America Capital Management
New York
$4.07M +$21.7K +427 +0.6%
Canada Pension Plan Investment Board
102
Canada Pension Plan Investment Board
Ontario, Canada
$3.87M +$579K +11,400 +20%
State Board of Administration of Florida Retirement System
103
State Board of Administration of Florida Retirement System
Florida
$3.82M – – –
Morgan Stanley
104
Morgan Stanley
New York
$3.72M +$954K +18,767 +40%
BAMS
105
Bellevue Asset Management (Switzerland)
Switzerland
$3.68M – – –
ARTA
106
A.R.T. Advisors
New York
$3.51M -$2.34M -46,100 -43%
MLICM
107
Metropolitan Life Insurance Company (MetLife)
New York
$3.36M +$29.5K +581 +1%
PNC Financial Services Group
108
PNC Financial Services Group
Pennsylvania
$3.28M +$436K +8,578 +17%
PA
109
Profund Advisors
Maryland
$3.27M -$11.4K -225 -0.4%
ACP
110
Acuta Capital Partners
California
$3.17M +$2.85M +56,000 New
OM
111
Opaleye Management
Massachusetts
$3.11M -$3.56M -70,000 -56%
UBS Group
112
UBS Group
Switzerland
$3.08M +$1.95M +38,426 +239%
DBG
113
De Burlo Group
Massachusetts
$3.02M – – –
RFC
114
Russell Frank Company
Washington
$3.01M +$262K +5,148 +11%
AIG
115
American International Group
New York
$2.9M -$9.5K -187 -0.4%
ACM
116
Atika Capital Management
New York
$2.83M -$1.19M -23,500 -32%
Barclays
117
Barclays
United Kingdom
$2.83M -$1.77M -34,791 -41%
GH
118
GAM Holding
Switzerland
$2.81M +$2.53M +49,700 New
IGIM
119
I.G. Investment Management
Manitoba, Canada
$2.55M +$2.29M +45,000 New
ACM
120
Asymmetry Capital Management
California
$2.31M -$438K -8,612 -17%
HI
121
HBK Investments
Texas
$2.29M -$3.85M -75,734 -65%
HCMT
122
Highland Capital Management (Texas)
Texas
$2.06M -$6.86M -134,902 -79%
ACI
123
Alpha Cubed Investments
California
$2.04M – – –
HMS
124
Hanseatic Management Services
New Mexico
$2.02M -$7.47K -147 -0.4%
TCM
125
Traynor Capital Management
Pennsylvania
$2M +$93.3K +1,835 +5%
3 4
5
6 7

NBIX Hedge Fund Activity: Q4 2015 in Review

218 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q4 2015, worth a combined $4.7B — up 43% from $3.29B a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new NBIX positions and 23 closed out — a net gain of 12 holders — while 92 added to existing stakes and 72 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $43.9M. The largest seller was OrbiMed, cutting an estimated $66.1M.

  • 218 institutional investors held Neurocrine Biosciences (NBIX) as of Q4 2015, up from 207 in Q3 2015.
  • Funds reported $4.7B of Neurocrine Biosciences stock for Q4 2015, up 43% quarter-over-quarter.
  • 35 funds opened new Neurocrine Biosciences positions in Q4 2015 and 23 closed out, a net change of +12 holders.
  • The largest Neurocrine Biosciences buyer in Q4 2015 was T. Rowe Price Associates, an estimated $43.9M added.
  • The largest Neurocrine Biosciences seller in Q4 2015 was OrbiMed, an estimated $66.1M sold.

Based on aggregated 13F filings for Q4 2015.